Interferons for viral hepatitis.
Terrault
N
N
Mount Sinai Hospital, Department of Medicine, University of Toronto, Canada.
Feinman
S V
SV
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000917:Antibody Formation; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006679:HIV Seropositivity / Q000150:complications; D006521:Hepatitis, Chronic / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000009:adverse effects / Q000276:immunology / Q000502:physiology / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use; D008111:Liver Function Tests; D016031:Liver Transplantation; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D007372:Interferons